Pulminiq Inhaled Cyclosporine Approval Will Be Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron expects approval of the inhaled cyclosporine Pulminiq to be delayed by three months while FDA reviews additional analyses of pivotal data